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ABSTRACT
Background: DLG5 p.R30Q has been reported to be
associated with Crohn disease (CD), but this association
has not been replicated in most studies. A recent analysis
of gender-stratified data from two case–control studies
and two population cohorts found an association of DLG5
30Q with increased risk of CD in men but not in women
and found differences between 30Q population frequen-
cies for males and females. Male–female differences in
population allele frequencies and male-specific risk could
explain the difficulty in replicating the association with CD.
Methods: DLG5 R30Q genotype data were collected for
patients with CD and controls from 11 studies that did not
include gender-stratified allele counts in their published
reports and tested for male–female frequency differences
in controls and for case–control frequency differences in
men and in women.
Results: The data showed no male–female allele
frequency differences in controls. An exact conditional
test gave marginal evidence that 30Q is associated with
decreased risk of CD in women (p = 0.049, OR = 0.87,
95% CI 0.77 to 1.00). There was also a trend towards
reduced 30Q frequencies in male patients with CD
compared with male controls, but this was not significant
at the 0.05 level (p = 0.058, OR = 0.87, 95% CI 0.74 to
1.01). When data from this study were combined with
previously published, gender-stratified data, the 30Q allele
was found to be associated with decreased risk of CD in
women (p = 0.010, OR = 0.86, 95% CI 0.76 to 0.97), but
not in men.
Conclusion: DLG5 30Q is associated with a small
reduction in risk of CD in women.
Inflammatory bowel disease (IBD; OMIM 266600)
comprises Crohn disease (CD; OMIM 266600) and
ulcerative colitis (UC; OMIM 191390).
Epidemiological and genetic studies have demon-
strated that genes play an important role in the
pathogenesis of IBD.1–6 Genetic variants associated
with CD have been identified and replicated in the
CARD15/NOD2 gene (OMIM 605956)7–9 and in the
chromosome 5q31 region (OMIM 606348),10–13 and
recently, the first generation of whole-genome
association studies have identified multiple new
susceptibility variants.14–19
In 2004, Stoll et al described an association
between IBD and DLG5 variants (DLG5:
Drosophila Discs Large Homolog 5 (OMIM
604090). In particular, p.R30Q (c.89GRA,
rs1248696, previously reported as c.113GRA) was
found to be associated with IBD in a German
family cohort. Stoll et al20 replicated the R30Q
association with CD in a European case–control
cohort and found a non-significant overtransmis-
sion of the 30Q allele in patients with CD in a
German/UK family cohort. Subsequently, Daly et
al21 replicated the association of 30Q with CD in
one of two case–control cohorts and in a family
cohort. However, subsequent studies have failed to
replicate the association of DLG5 30Q with CD.22–34
Recently, Friedrichs et al35 examined gender-
stratified data from the case–control cohorts
showing association in the initial two DLG5
studies,20 21 and found that the DLG5 30Q allele
was a risk factor for CD in men but not in women,
and that the 30Q allele frequency was significantly
lower in male compared with female controls (0.05
vs 0.11). Friedrichs et al35 genotyped R30Q in two
additional control samples: a sample of 190 male
and 271 female participants from Germany and in
a newborn sample of 301 male and 299 female
infants from Wisconsin, USA. For all three samples
(combined control cohort, the German population
sample and the Wisconsin population sample) the
DLG5 30Q allele frequency was lower in male than
in female subjects and the differences were
significant at the 0.05 level. The presence of the
male–female allele frequency differences in the
newborn sample suggests that the allele frequency
differences are due to prenatal processes rather
than selection later in life and Friedrichs et al35
proposed that the allele frequency differences were
a consequence of a gender-dependent transmission
ratio distortion.
Differences in male and female allele frequencies
combined with male–specific risk could explain the
difficulties that have been encountered in replicat-
ing the association of 30Q with CD, as the
estimated effect size would depend on the propor-
tion of male cases and controls in the study. If the
minor allele increases risk in men but not in
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women and if the frequency in male patients with CD is less
than the minor allele frequency in females in a population, then
the 30Q allele would be a risk allele in a study of female patients
with CD and male controls, but would be a protective allele in a
study of male patients with CD and female controls.
Replication of association could be further complicated by
differences in effect sizes between populations, owing to
interaction of R30Q with other genetic and environmental
factors that vary between populations.
Most studies investigating R30Q were published prior to the
report of Friedrichs et al,35 which first described differences in
male and female R30Q population frequencies and male–specific
risk. Consequently, in most DLG5 studies, genotype data
stratified by gender have not been reported. In this study, we
analysed male and female R30Q allele counts from 11 previous
DLG5 case–control studies that did not report gender-stratified
data. We tested R30Q for association with CD in men and in
women, and tested for differences in male and female control
allele frequencies.
METHODS
Study participants
Published association studies of DLG5 were identified through
PubMed using a search with the keyword ‘‘DLG5’’. All
association studies had sampled from Caucasian populations.
The limited available evidence indicates that the DLG5 R30Q
polymorphism is absent in populations from Asia and Africa.36 37
We identified 12 case–control association studies of DLG5 R30Q
and IBD in Caucasian populations, which had not reported
gender-stratified R30Q allele counts or frequencies. One of these
12 studies had a relatively high proportion of non-Caucasian
participants.38 Gender-stratified data from the remaining 11
DLG5 case–control studies22–27 29 30 32–34 are included in the
current study and represent 4707 patients with CD and 4973
controls from 12 case–control cohorts.
Allele counts reported in the current study may be greater or
less than allele counts in the original study if gender was not
available for some participants or if additional individuals from
the same population were genotyped for DLG5 R30Q subse-
quent to the initial study. Our dataset does not include data
from the Ashkenazi Jewish participants in the study of
Newman et al,29 nor the CD and control patients in the study
of Cucchiara et al32 who had previously been included in the
study of Friedrich et al,35. Local ethics committee approval was
obtained for each study that contributed gender-stratified data
to the current study.
All mutations are numbered at the cDNA level, indicated by a
‘‘c.’’ before the number. Position +1 corresponds to the A of the
ATG translation initiation codon located at nucleotide 401 in
the NM_004747.3 DLG5 mRNA reference sequence.
Statistical analysis
Statistical analysis was performed using R V.2.2.0 software.39
For comparison of male and female 30Q population frequencies,
allelic odds ratios (ORs) ,1.0 correspond to a lower 30Q allele
frequency in male than in female subjects. For case–control
analysis, allelic ORs ,1.0 correspond to a lower 30Q allele
frequency in patients with CD than in controls. Allelic ORs
with 95% confidence intervals (CIs) were calculated under the
assumption of Hardy–Weinberg equilibrium both in cases and
in controls.
The combined evidence for association was assessed with an
exact conditional test (conditional upon cohort). The exact test
was used in preference to the Cochran–Mantel–Haenszel test
because the exact test does not use an asymptotic approxima-
tion. Heterogeneity between studies was assessed using
Cochran’s Q statistic,40 which has a x2 distribution under the
null hypothesis of no heterogeneity between studies, and using
the I2 statistic,41 which is an estimate of the proportion of the
total variation that is due to heterogeneity between studies.
When there was evidence for heterogeneity between studies, we
performed a meta-analysis under a random effects model42 to
estimate the mean OR. Under a random effects model, the
variance of the allelic OR for each study population is assumed
to be drawn from a random distribution with variance d and the
variance of the estimated allelic OR is the sum of the sampling
variance and d. Estimates of mean OR under a random effects
model are calculated by weighting each study by the reciprocal
of the sampling variance of the OR to accounts for differences in
sample sizes.
RESULTS
Male and female DLG5 R30Q allele counts for 12 case–control
cohorts are given in table 1. Genotype counts in CD cases and in
controls were tested for departures from Hardy–Weinberg
equilibrium using an exact test.43 None of the tests for Hardy–
Table 1 Male and female DLG5 R30Q allele frequency data reported in this study
Study Population
Male patients with CD Male controls
OR (95% CI)
Female patients with
CD Female controls
OR (95% CI)n 30Q % n 30Q % n 30Q % n 30Q %
Browning, 200734 New Zealand 139 37 13.3 173 32 9.2 1.51 (0.91 to 2.49) 250 60 12.0 237 50 10.5 1.16 (0.78 to 1.72)
Cucchiara, 200732 Italian 92 5 2.7 153 36 11.8 0.21 (0.08 to 0.54) 65 7 5.4 101 16 7.9 0.66 (0.26 to 1.66)
Pearce, 200733 British 270 40 7.4 178 37 10.4 0.69 (0.43 to 1.10) 360 82 11.4 278 47 8.5 1.39 (0.95 to 2.03)
Ferraris, 200626 Italian 69 14 10.1 63 13 10.3 0.98 (0.44 to 2.18) 65 9 6.9 47 8 8.5 0.80 (0.30 to 2.16)
Lakatos, 200627 Hungarian 309 71 11.5 72 26 18.1 0.59 (0.36 to 0.96) 330 73 11.1 78 19 12.2 0.90 (0.52 to 1.54)
Tremelling, 200630 British 168 39 11.6 330 75 11.4 1.02 (0.68 to 1.55) 326 64 9.8 426 100 11.7 0.82 (0.59 to 1.14)
Newman, 200629 Canadian 141 27 9.6 171 33 9.6 0.99 (0.58 to 1.69) 172 26 7.6 512 114 11.1 0.65 (0.42 to 1.02)
Bu¨ning, 200625 German 90 14 7.8 212 42 9.9 0.77 (0.41 to 1.44) 148 20 6.8 208 40 9.6 0.68 (0.39 to 1.19)
Bu¨ning, 200625 Hungarian 65 11 8.5 95 19 10.0 0.83 (0.38 to 1.81) 82 12 7.3 110 27 12.3 0.56 (0.28 to 1.15)
To¨ro¨k, 200523 South German 225 45 10.0 594 128 10.8 0.92 (0.64 to 1.32) 252 50 9.9 378 82 10.8 0.91 (0.62 to 1.31)
Noble, 2005 22 Scottish 142 28 9.9 128 33 12.9 0.74 (0.43 to 1.26) 214 45 10.5 128 34 13.3 0.77 (0.48 to 1.23)
Vermeire, 200524 Flemish 295 62 10.5 137 24 8.8 1.22 (0.75 to 2.01) 438 90 10.3 164 41 12.5 0.80 (0.54 to 1.19)
Cumulative report — 2005 — — 2306 — — 0.87 (0.74 to 1.01) 2702 — — 2667 — — 0.87 (0.77 to 1.00)
Study, population, case and control sample sizes, 30Q allele counts, 30Q allele frequencies and ORs with 95% CIs are given.
The OR and 95% CI for the cumulative data were calculated using an exact conditional test.
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Weinberg equilibrium were significant at the 0.05 level after
correcting for multiple testing using a Bonferroni correction.
There was no support for differences in 30Q allele frequencies
between male and female controls in our data (exact test
OR = 0.99, 95% CI 0.87 to 1.13) and there was no evidence of
heterogeneity of OR between populations (Q = 8.83, 11 degrees
of freedom (df), p = 0.64, I2 = 0.00).
In our female case–control data, there was a lower 30Q
frequency in female patients with CD compared with female
controls (exact test p = 0.049, OR = 0.87, 95% CI 0.77 to 1.00)
and there was no evidence of heterogeneity of OR between
female populations (Q = 12.7, 11 df, p = 0.32, I2 = 0.13).
In our male case–control data, there was marginal evidence of
heterogeneity of OR (Q = 19.9, 11 df, p = 0.047, I2 = 0.45), so
we performed analysis using a random effects model, which
allows for heterogeneity of ORs between populations, in
addition to analysis using an exact test, which assumes
homogeneity of effect between populations. For the male data,
the exact test was not significant at the 0.05 level (p = 0.058,
OR = 0.87, 95% CI 0.74 to 1.01) and the 95% CI for the mean
OR under a random effects model included 1.0 (mean
OR = 0.86, 95% CI 0.70 to 1.06).
Combining our male and female data, there was marginal
evidence for heterogeneity of ORs (Q = 20.0, 11 df, p = 0.046,
I2 = 0.45) and our combined male and female data supported an
association of 30Q with reduced risk of CD (random effects
mean OR = 0.85, 95% CI 0.74 to 0.98).
In summary, we found no male–female differences in DLG5
R30Q frequencies among controls, but our data gives marginal
evidence that the 30Q was associated with reduced risk of CD in
both men and women.
We next compared our findings with previously published
gender-stratified R30Q data,28 31 35 which include gender-strati-
fied data from Stoll et al20 and Daly et al21 Population, sample
sizes, ORs and CIs are shown in the figures for male controls
and female controls (fig 1), for female patients with CD and
female controls (fig 2) and for male patients with CD and male
controls (fig 3). In all three figures, the sampled population, the
sample size, the sample OR and 95% CIs for the sample OR are
given. The horizontal dotted line divides previously published
data (above the line) and data in the current study (below the
line). The ORs with 95% CI for the pooled data from previous
studies, for the pooled data from the current study and for the
pooled data from all studies are calculated using a random
effects model. Allelic ORs are graphed using a logarithmic scale
for the x axis.
Published gender-stratified data from previous studies show
no evidence of heterogeneity of ORs in male controls versus
female controls, but give strong evidence for reduced 30Q
frequency in males compared with females (exact test p = 1027,
Figure 1 Odds ratio of DLG5 R30Q in
male and female controls. Odds ratios
,1.0 correspond to decreased 30Q
frequency in males. The horizontal dotted
line divides previously published data
(above the line) and data in the current
study (below the line).
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OR = 0.58, 95% CI 0.47 to 0.71).28 31 35. This contrasts with our
data, which showed no male–female 30Q frequency differences
(OR = 0.99, see fig 1). When our data were combined with
previously published data using a random effects model, the
estimated mean OR was 0.84 with 95% CI 0.72 to 0.98. Our
large sample of 4973 controls showed no difference in male and
female 30Q frequencies, but the magnitude of the effect
described in previous studies is sufficiently large that analysis
of the combined data shows allele frequency differences. The
discordance between our data and previously published data
suggests that data from additional studies are needed and that it
would be premature to conclude that male–female allele
frequency differences exist or are absent for DLG5 R30Q.
Female data from previous studies show a trend toward
reduced 30Q allele frequency in female patients with CD
compared with female controls (exact test p = 0.088, OR = 0.79,
95% CI 0.61 to 1.04). This is consistent with our data. When our
data were combined with previously published female data,
there was a significant reduction in 30Q frequency in female
patients with CD compared with female controls (exact test
p = 0.010, OR = 0.86, 95% CI 0.76 to 0.97). None of the female
datasets (our female data, previously published female data or
combined female data), showed evidence for heterogeneity of
ORs (combined data Q = 19.0, 16 df, p = 0.27, I2 = 0.16).
Published male data from previous studies show a significant
increase in 30Q frequency in male patients with CD compared
with male controls (exact test p = 0.0020, OR = 1.60, 95% CI
1.18 to 2.17). In contrast, our data show a reduced 30Q
frequency in male patients with CD compared with controls
(OR = 0.87). Consequently, when our male data are combined
with previously published male data, there is evidence for
heterogeneity of ORs between studies (Q = 36.5, 16 df,
p = 0.0025, I2 = 0.56), but no evidence that the mean OR differs
from 1.0 under a random effects model (mean OR = 0.99, 95%
CI 0.80 to 1.22).
DISCUSSION
Evidence for association of the 30Q allele with increased risk for
CD is provided by the initial two DLG5 studies20 21 but attempts
to replicate this association generally have not been success-
ful.22–34 The first four published whole-genome association
studies for CD, three of which genotyped the R30Q variant,
did not report DLG5 variants to be associated with CD in their
initial published analyses.15 16 18 19 It has been suggested that
differences in male and female population allele frequencies and
different effects in males compared with females could make it
difficult to replicate the association of 30Q with CD.
In this study, we report gender-stratified data for 4311 males
and 5369 females from 12 case–control cohorts. We have tested
our data for male–female control frequency differences and for
case–control frequency differences in men and in women and
we place our data in the context of previously published gender-
stratified R30Q data.
The most striking difference between the data in the current
study and data in previous studies is the absence of male and
female population allele frequency differences for DLG5 R30Q
Figure 2 Odds ratio of DLG5 R30Q in
female patients with CD and female
controls. Odds ratios,1.0 correspond to
decreased 30Q frequency in patients with
CD. The horizontal dotted line divides
previously published data (above the line)
and data in the current study (below the
line).
Letter to JMG
J Med Genet 2008;45:36–42. doi:10.1136/jmg.2007.050773 39
in our data (OR = 0.99), but the presence of strong differences
in previous data (OR = 0.58, p = 1027). It is unlikely that
sampling variability alone can account for this difference. When
we extend CIs to have 99.5% confidence, the CI for the OR in
our data and the CI for the OR in previously published data are
disjoint.
We considered whether population differences could account
for the absence of male–female allele frequency differences in
our study. The use of ‘‘healthy’’ controls versus unphenotyped
population controls is unlikely to explain the differences as CD
has ,1% prevalence.44 Different age distributions between
control cohorts is also unlikely to explain the difference, as
previous studies have found male–female allele frequency
differences in both newborn and adult population samples.
Undetected population stratification could result in the
presence (or absence) of male–female allele frequency differ-
ences if male and female controls tended to be sampled from
different subpopulations.
We investigated the possibility that discrepancies between
our data and previously published data could be due to
genotyping artefacts. In particular, we examined the possibility
that nonspecific primer binding could lead to different distribu-
tions of missing and incorrect genotypes in men and women.
We compared the DLG5 cDNA sequence (NM_004747) against
the human genome using the NCBI MEGABLAST tool (http://
www.ncbi.nlm.nih.gov/BLAST/), but found no homologies
other than DLG5. A variety of genotyping platforms has been
used in the published DLG5 studies and we were not able to
trace the difference between published data and our data to the
use of any single genotyping platform.
For the studies that have reported the primers used to
genotype the R30Q variant, we tested the specificity of primers
using the NCBI Nucleotide BLAST tool (‘‘search for short nearly
exact matches’’). We did not identify any hits on the X or Y
chromosome that could lead to non-specific binding in men or
women.
A combination of sampling variability combined with a
reporting bias may help explain the difference between the set
of DLG5 studies that have reported gender-stratified data and
the set of DLG5 studies in the current study. Studies that
observe a significant male–female allele frequency difference in
controls would presumably be more likely to report gender-
stratified control data.
Fortunately, many of the whole-genome association studies
will genotype the DLG5 R30Q variant in their control cohorts.
The R30Q variant is not highly correlated with any other
known variant,20 and no single-nucleotide polymorphisms
genotyped for the HapMap project37 that are within 200 kb of
R30Q have pairwise squared correlation coefficients r2.0.3 in
Caucasians. Consequently, the DLG5 R30Q polymorphism will
generally be genotyped in whole-genome association studies
that use tagging markers, such as those using the Illumina
genotyping platform.45 We expect that these whole-genome
association studies will provide the additional genotype data
necessary to confirm or refute the presence of male–female
population allele frequency differences for DLG5 R30Q.
Figure 3 Odds ratio of DLG5 R30Q in
male patients with CD and male controls.
Odds ratios ,1.0 correspond to
decreased 30Q frequency in patients with
CD. The horizontal dotted line divides
previously published data (above the line)
and data in the current study (below the
line).
Letter to JMG
40 J Med Genet 2008;45:36–42. doi:10.1136/jmg.2007.050773
Previously published male data show higher 30Q frequency in
male patients with CD compared with male controls, but our
male data show a trend toward lower 30Q frequencies in male
patients with CD compared with male controls. When the data
are combined, the estimated mean OR is close to 1.0
(OR = 0.97), so the association of DLG5 R30Q with CD in
men appears doubtful. We note that there is evidence for
heterogeneity of ORs between studies in the combined data
(p = 0.0020). If heterogeneity between ORs in different male
populations does exist, then an estimated mean OR of 0.97
indicates that the 30Q allele is associated with a reduced risk in
some male populations and increased risk in other male
populations, which seems unlikely.
Our female data are consistent with previously published
female data, and the combined data indicate that 30Q is
associated with reduced risk of CD. Thus, although a significant
decrease in female 30Q frequency is seen in only 1 of 17 cohorts
studied (fig 2), the trend toward lower ORs seen in figure 2
supports an association of 30Q with reduced risk of CD in
women (exact test p = 0.010, OR = 0.86, 95% CI 0.76 to 0.97).
The presence of female-specific effects could arise out of
interaction with gender-specific risk factors such as oral
contraceptive use.46 47 Interestingly, Purmonen et al48 showed
that DLG5 is a hormonally regulated member of the MAGUK
gene family and suggested DLG5 to be a primary progesterone
target gene in human breast cancer cells. This makes biological
sense, as progesterone is uniquely a female hormone, produced
at significant levels from puberty. Synthetic forms of progester-
one are also a significant component of the combined oral
contraceptive pill and a major component of the progesterone-
only contraceptive pill. These associations may help provide an
explanation for observed gender specific differences in incidence
of CD.49
The estimated OR of 0.84 for the minor 30Q allele is
equivalent to an OR of 1.16 for the major R30 allele. The modest
DLG5 30Q allele frequency (,0.10) and the small estimated
effect size in women indicates that large collaborative efforts
will be needed to confirm the association of 30Q with reduced
risk of CD in women.
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